Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer
In an attempt to improve the curative potential of surgery, 46 patients with unresectable Stage IIIA (Clinical N2) non-small cell lung cancer received neoadjuvant chemotherapy with cisplatin and etoposide. After 2 or 3 cycles, 45 patients were evaluable for response; the overall response rate was 82...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 1994-02, Vol.17 (1), p.64-67 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 67 |
|---|---|
| container_issue | 1 |
| container_start_page | 64 |
| container_title | American journal of clinical oncology |
| container_volume | 17 |
| creator | DARWISH, S MINOTTI, V DAVIS, S LATINI, P TONATO, M CRINO, L ROSSETTI, R MARANZANO, E CHECCAGLINI, F FIASCHINI, P MERCATI, U PENZA, O VITALI, R |
| description | In an attempt to improve the curative potential of surgery, 46 patients with unresectable Stage IIIA (Clinical N2) non-small cell lung cancer received neoadjuvant chemotherapy with cisplatin and etoposide. After 2 or 3 cycles, 45 patients were evaluable for response; the overall response rate was 82% (37/45) with 3 complete and 34 partial responses. Toxicity was primarily hematologic. Surgical exploration was performed on 35 patients, but resection was possible in only 33 (73%). Of these, 28 resections were complete (62%). Four patients (2CR, 2PR; 9%) had no tumor in biopsy specimen. Three deaths were surgery-related. Median survival of the entire 46 patients was 24.5 months with a 2-year survival of 53%. Cisplatin and etoposide is an effective chemotherapeutic regimen for regionally advanced non-small cell lung cancer; the resection and survival rates justify further trials to compare this approach to other treatment modalities. |
| doi_str_mv | 10.1097/00000421-199402000-00014 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00000421_199402000_00014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8311011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c349t-1aa7361cc25d5f7a6a3bf3d7f0172e69a203e200b48939526bf7792fb31a61433</originalsourceid><addsrcrecordid>eNo9kFFLwzAUhYMoc05_gpAHH_Qhmpu0zfI4xtTCmC8Kgg_lNk1GR5eWphP892ZuLpBcwr3ncs5HCAX-CFyrJ74_iQAGWidcxA-LF5IzMoZUKpak8vOcjLlQikklxSW5CmETR9KMqxEZTSUABxiTr5VtsdrsvtEP1NSha3CoPUVfUTu0XRvqylLX9jQMuLY0z_MZvTdN7WuDDV2JB-pbz8IWm4YaG59m59fUoDe2vyYXDptgb451Qj6eF-_zV7Z8e8nnsyUzMtEDA0QlMzBGpFXqFGYoSycr5TgoYTONgksbI5bJVEudiqx0SmnhSgmYQSLlhEwPe03fhtBbV3R9vcX-pwBe7HEV_7iKE67iD1eU3h6k3a7c2uokPPKJ_btjH0MM7PoYrA6nsWgn-knlL9WhcK0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>DARWISH, S ; MINOTTI, V ; DAVIS, S ; LATINI, P ; TONATO, M ; CRINO, L ; ROSSETTI, R ; MARANZANO, E ; CHECCAGLINI, F ; FIASCHINI, P ; MERCATI, U ; PENZA, O ; VITALI, R</creator><creatorcontrib>DARWISH, S ; MINOTTI, V ; DAVIS, S ; LATINI, P ; TONATO, M ; CRINO, L ; ROSSETTI, R ; MARANZANO, E ; CHECCAGLINI, F ; FIASCHINI, P ; MERCATI, U ; PENZA, O ; VITALI, R</creatorcontrib><description>In an attempt to improve the curative potential of surgery, 46 patients with unresectable Stage IIIA (Clinical N2) non-small cell lung cancer received neoadjuvant chemotherapy with cisplatin and etoposide. After 2 or 3 cycles, 45 patients were evaluable for response; the overall response rate was 82% (37/45) with 3 complete and 34 partial responses. Toxicity was primarily hematologic. Surgical exploration was performed on 35 patients, but resection was possible in only 33 (73%). Of these, 28 resections were complete (62%). Four patients (2CR, 2PR; 9%) had no tumor in biopsy specimen. Three deaths were surgery-related. Median survival of the entire 46 patients was 24.5 months with a 2-year survival of 53%. Cisplatin and etoposide is an effective chemotherapeutic regimen for regionally advanced non-small cell lung cancer; the resection and survival rates justify further trials to compare this approach to other treatment modalities.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/00000421-199402000-00014</identifier><identifier>PMID: 8311011</identifier><identifier>CODEN: AJCODI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Chemotherapy ; Chemotherapy, Adjuvant ; Cisplatin - administration & dosage ; Etoposide - administration & dosage ; Feasibility Studies ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Male ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Pharmacology. Drug treatments ; Pilot Projects ; Treatment Outcome</subject><ispartof>American journal of clinical oncology, 1994-02, Vol.17 (1), p.64-67</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c349t-1aa7361cc25d5f7a6a3bf3d7f0172e69a203e200b48939526bf7792fb31a61433</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3955265$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8311011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DARWISH, S</creatorcontrib><creatorcontrib>MINOTTI, V</creatorcontrib><creatorcontrib>DAVIS, S</creatorcontrib><creatorcontrib>LATINI, P</creatorcontrib><creatorcontrib>TONATO, M</creatorcontrib><creatorcontrib>CRINO, L</creatorcontrib><creatorcontrib>ROSSETTI, R</creatorcontrib><creatorcontrib>MARANZANO, E</creatorcontrib><creatorcontrib>CHECCAGLINI, F</creatorcontrib><creatorcontrib>FIASCHINI, P</creatorcontrib><creatorcontrib>MERCATI, U</creatorcontrib><creatorcontrib>PENZA, O</creatorcontrib><creatorcontrib>VITALI, R</creatorcontrib><title>Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>In an attempt to improve the curative potential of surgery, 46 patients with unresectable Stage IIIA (Clinical N2) non-small cell lung cancer received neoadjuvant chemotherapy with cisplatin and etoposide. After 2 or 3 cycles, 45 patients were evaluable for response; the overall response rate was 82% (37/45) with 3 complete and 34 partial responses. Toxicity was primarily hematologic. Surgical exploration was performed on 35 patients, but resection was possible in only 33 (73%). Of these, 28 resections were complete (62%). Four patients (2CR, 2PR; 9%) had no tumor in biopsy specimen. Three deaths were surgery-related. Median survival of the entire 46 patients was 24.5 months with a 2-year survival of 53%. Cisplatin and etoposide is an effective chemotherapeutic regimen for regionally advanced non-small cell lung cancer; the resection and survival rates justify further trials to compare this approach to other treatment modalities.</description><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cisplatin - administration & dosage</subject><subject>Etoposide - administration & dosage</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Treatment Outcome</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kFFLwzAUhYMoc05_gpAHH_Qhmpu0zfI4xtTCmC8Kgg_lNk1GR5eWphP892ZuLpBcwr3ncs5HCAX-CFyrJ74_iQAGWidcxA-LF5IzMoZUKpak8vOcjLlQikklxSW5CmETR9KMqxEZTSUABxiTr5VtsdrsvtEP1NSha3CoPUVfUTu0XRvqylLX9jQMuLY0z_MZvTdN7WuDDV2JB-pbz8IWm4YaG59m59fUoDe2vyYXDptgb451Qj6eF-_zV7Z8e8nnsyUzMtEDA0QlMzBGpFXqFGYoSycr5TgoYTONgksbI5bJVEudiqx0SmnhSgmYQSLlhEwPe03fhtBbV3R9vcX-pwBe7HEV_7iKE67iD1eU3h6k3a7c2uokPPKJ_btjH0MM7PoYrA6nsWgn-knlL9WhcK0</recordid><startdate>199402</startdate><enddate>199402</enddate><creator>DARWISH, S</creator><creator>MINOTTI, V</creator><creator>DAVIS, S</creator><creator>LATINI, P</creator><creator>TONATO, M</creator><creator>CRINO, L</creator><creator>ROSSETTI, R</creator><creator>MARANZANO, E</creator><creator>CHECCAGLINI, F</creator><creator>FIASCHINI, P</creator><creator>MERCATI, U</creator><creator>PENZA, O</creator><creator>VITALI, R</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199402</creationdate><title>Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer</title><author>DARWISH, S ; MINOTTI, V ; DAVIS, S ; LATINI, P ; TONATO, M ; CRINO, L ; ROSSETTI, R ; MARANZANO, E ; CHECCAGLINI, F ; FIASCHINI, P ; MERCATI, U ; PENZA, O ; VITALI, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c349t-1aa7361cc25d5f7a6a3bf3d7f0172e69a203e200b48939526bf7792fb31a61433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cisplatin - administration & dosage</topic><topic>Etoposide - administration & dosage</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DARWISH, S</creatorcontrib><creatorcontrib>MINOTTI, V</creatorcontrib><creatorcontrib>DAVIS, S</creatorcontrib><creatorcontrib>LATINI, P</creatorcontrib><creatorcontrib>TONATO, M</creatorcontrib><creatorcontrib>CRINO, L</creatorcontrib><creatorcontrib>ROSSETTI, R</creatorcontrib><creatorcontrib>MARANZANO, E</creatorcontrib><creatorcontrib>CHECCAGLINI, F</creatorcontrib><creatorcontrib>FIASCHINI, P</creatorcontrib><creatorcontrib>MERCATI, U</creatorcontrib><creatorcontrib>PENZA, O</creatorcontrib><creatorcontrib>VITALI, R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DARWISH, S</au><au>MINOTTI, V</au><au>DAVIS, S</au><au>LATINI, P</au><au>TONATO, M</au><au>CRINO, L</au><au>ROSSETTI, R</au><au>MARANZANO, E</au><au>CHECCAGLINI, F</au><au>FIASCHINI, P</au><au>MERCATI, U</au><au>PENZA, O</au><au>VITALI, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>1994-02</date><risdate>1994</risdate><volume>17</volume><issue>1</issue><spage>64</spage><epage>67</epage><pages>64-67</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><coden>AJCODI</coden><abstract>In an attempt to improve the curative potential of surgery, 46 patients with unresectable Stage IIIA (Clinical N2) non-small cell lung cancer received neoadjuvant chemotherapy with cisplatin and etoposide. After 2 or 3 cycles, 45 patients were evaluable for response; the overall response rate was 82% (37/45) with 3 complete and 34 partial responses. Toxicity was primarily hematologic. Surgical exploration was performed on 35 patients, but resection was possible in only 33 (73%). Of these, 28 resections were complete (62%). Four patients (2CR, 2PR; 9%) had no tumor in biopsy specimen. Three deaths were surgery-related. Median survival of the entire 46 patients was 24.5 months with a 2-year survival of 53%. Cisplatin and etoposide is an effective chemotherapeutic regimen for regionally advanced non-small cell lung cancer; the resection and survival rates justify further trials to compare this approach to other treatment modalities.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>8311011</pmid><doi>10.1097/00000421-199402000-00014</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 1994-02, Vol.17 (1), p.64-67 |
| issn | 0277-3732 1537-453X |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00000421_199402000_00014 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Chemotherapy, Adjuvant Cisplatin - administration & dosage Etoposide - administration & dosage Feasibility Studies Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medical sciences Middle Aged Neoplasm Staging Pharmacology. Drug treatments Pilot Projects Treatment Outcome |
| title | Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T17%3A04%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20cisplatin%20and%20etoposide%20for%20stage%20IIIA%20(clinical%20N2)%20non-small%20cell%20lung%20cancer&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=DARWISH,%20S&rft.date=1994-02&rft.volume=17&rft.issue=1&rft.spage=64&rft.epage=67&rft.pages=64-67&rft.issn=0277-3732&rft.eissn=1537-453X&rft.coden=AJCODI&rft_id=info:doi/10.1097/00000421-199402000-00014&rft_dat=%3Cpubmed_cross%3E8311011%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8311011&rfr_iscdi=true |